text_1: Experts Issue New Guidelines on Breast Cancer Drugs
text_2: "The American Society of Clinical Oncologists (ASCO) has released updated guidelines on adjuvant endocrine therapy in breast cancer. The story met many of our criteria, but missed the mark by insinuating that all postmenopausal women with hormone receptor-postiive breast cancer should use aromatase inhibitors: ""The committee preparing the guidelines recommended, therefore, that all postmenopausal women with this type of breast cancer use aromatase inhibitors either before or after tamoxifen."""